Diabetic Nephropathy Global Clinical Trials Review, H2, 2017

Diabetic Nephropathy Global Clinical Trials Review, H2, 2017


  • Products Id :- GDHC4384CTIDB
  • |
  • Pages: 317
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Nephropathy Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, "Diabetic Nephropathy Global Clinical Trials Review, H2, 2017" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 27

In Progress Trials by Phase 28

Clinical Trials by Trial Status 29

Clinical Trials by End Point Status 31

Subjects Recruited Over a Period of Time 32

Clinical Trials by Sponsor Type 33

Prominent Sponsors 34

Top Companies Participating in Diabetic Nephropathy Therapeutics Clinical Trials 36

Prominent Drugs 38

Latest Clinical Trials News on Diabetic Nephropathy 39

Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert 39

Jun 12, 2017: Prometic Life Sciences Present Data on PBI-4547 at 2017 American Diabetes Association 77th Scientific Sessions 39

May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 39

Clinical Trial Profile Snapshots 40

Appendix 315

Abbreviations 315

Definitions 315

Research Methodology 316

Secondary Research 316

About GlobalData 317

Contact Us 317

Source 317

List of Figures

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2017* 8

Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12

Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13

Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14

Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15

Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16

Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 17

Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 22

Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27

Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29

Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32

Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38

GlobalData Methodology 316

List of Tables

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Region, 2017* 8

Diabetic Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10

Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Diabetic Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12

Diabetic Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13

Diabetic Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2017* 14

Diabetic Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15

Diabetic Nephropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16

Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 18

Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Diabetic Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21

Proportion of Diabetic Nephropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 23

Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Diabetic Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2017* 27

Diabetic Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28

Diabetic Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30

Diabetic Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32

Diabetic Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37

Diabetic Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pfizer Inc

Eli Lilly and Company

Novartis AG

Mitsubishi Chemical Holdings Corp

Daiichi Sankyo Company Ltd

Steno Diabetes Center A/S

Bayer AG

C. H. Boehringer Sohn AG & Co KG

AbbVie Inc

NephroGenex Inc

Diabetic Nephropathy Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Diabetic Nephropathy, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania

select a license
Single User License
USD 2500 INR 177450
Site License
USD 5000 INR 354900
Corporate User License
USD 7500 INR 532350

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com